IMMX - Immix Biopharma, Inc.

QQQ $ 442.96 $ 1.02 (0.23 %)

DIA $ 394.52 $ -0.72 (-0.18 %)

SPY $ 520.64 $ 0.07 (0.01 %)

TLT $ 90.36 $ 0.23 (0.26 %)

GLD $ 217.46 $ -2.45 (-1.12 %)

Previous Close

$ 2.16

Open

$ 2.14

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 2.13 - $ 2.19

52 Week Range

$ 1.40 - $ 7.75

Volume

79,434

Average Volume

Market Cap

50.63M

Beta (5Y Monthly)

$ 0.70

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-09-2024	03-31-2024	10-Q
2	03-29-2024	12-31-2023	10-K
3	11-10-2023	09-30-2023	10-Q
4	08-11-2023	06-30-2023	10-Q
5	05-12-2023	03-31-2023	10-Q
6	03-27-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-12-2022	06-30-2022	10-Q
9	05-13-2022	03-31-2022	10-Q
10	03-28-2022	12-31-2021	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

$immix-biopharma-reports-nxc-201-relapsedrefractory-al-amyloidosis-clinical-data-in-asgct-2024-oral-presentation$

Immix Biopharma Reports NXC-201 Relapsed/R...
05/10/2024 13:36:32

92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 pa...

Immix Biopharma Awarded European Union Orp...
04/29/2024 13:39:46

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EU...

Immix Biopharma On Track To Dose NXC-201 U...
04/18/2024 13:46:29

Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-...

Immix Biopharma Announces NXC-201 Clinical...
04/15/2024 13:38:49

Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore Ma...

Immix Biopharma Announces Comprehensive Ca...
03/20/2024 13:52:07

Immix Biopharma Announces 12-Month Progres...
02/21/2024 14:39:17

Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disea...

Immix Biopharma Awarded European Union Orp...
02/07/2024 14:41:01

European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EU...

Reported Late Monday, Immix Biopharma Pric...
02/06/2024 08:38:33

The gross proceeds to the Company from the offering are expected to be approximately $15 million, before deducting underwriting...

Immix Biopharma Shares Resume Trading
02/05/2024 20:39:09

Immix Biopharma Shares Halted On Circuit B...
02/05/2024 20:34:50

Immix Biopharma Shares Resume Trade
02/05/2024 20:33:29

Immix Biopharma Shares Halted On Circuit B...
02/05/2024 20:22:20

Immix Biopharma Announces Proposed Public ...
02/05/2024 20:21:49

Immix Biopharma, Inc. (NASDAQ:IMMX) (the "Company"), a clinical-stage biopharmaceutical company trailblazing cell thera...

Why Humana Shares Are Trading Lower By Ove...
01/25/2024 19:52:24

Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earning...

12-health-care-stocks-moving-in-thursdays-intraday-session

12 Health Care Stocks Moving In Thursday's...
01/25/2024 17:31:07

Immix Biopharma Statement On Jan. 2024 FDA...
01/24/2024 13:37:05

"We applaud FDA's vigilance. Relapsed/refractory AL Amyloidosis remains an unmet medical need with limited treatment op...

12-health-care-stocks-moving-in-fridays-intraday-session

12 Health Care Stocks Moving In Friday's I...
12/15/2023 17:31:25

12 Health Care Stocks Moving In Thursday's...
12/14/2023 17:32:05

$immix-biopharma-announces-100-overall-response-rate-and-70-complete-response-237-months-best-response-duration-ongoing-for-car-t-nxc-201-in-relapsedrefractory-al-amyloidosis-patients-at-ash-2023$

Immix Biopharma Announces 100% Overall Res...
12/11/2023 14:39:16

100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) ...

Immix Biopharma Announces FDA Approval Of ...
11/21/2023 14:46:55

NEXICART-2 to expand studies of NXC-201 in relapsed/refractory AL Amyloidosis to U.S. sites based on IND clearance72 patients p...